MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

neovascular age-related macular degeneration

  • Home
  • neovascular age-related macular degeneration
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
Posted inDiabetes & Endocrinology news Ophthalmology

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

Posted by By MedXY 06/10/2026
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
Read More
No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study
Posted inDiabetes & Endocrinology news Ophthalmology

No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study

Posted by By MedXY 06/04/2026
A multinational OHDSI network analysis found no meaningful association between semaglutide use and neovascular age-related macular degeneration among adults with type 2 diabetes across cohort and self-controlled designs.
Read More
  • Decoding Pancreatic Islet Single-Cell Transcriptomic Diversity Across Type 2 Diabetes Subtypes
  • Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Glucose Metabolism in Youths with Cystic Fibrosis: Insights from Continuous Glucose Monitoring
  • Approach to the Patient: Theranostics as Precision Medicine for Neuroendocrine Tumors
  • Charcot Neuro-Osteoarthropathy in Diabetes: High Risk of Hospitalization, Amputation, and Mortality Revealed by Regional Cohort Study
  • Gestational Diabetes Mellitus: Insights from 25 Years of Research on Early Risk, Prevention, and Long-Term Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top